GlassScriptPhysician profile
Lucy Elliott
NPI 1114299419
$1,890.04
in general payments reported to CMS, 2019-2025
21 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.63 · 2022: $41.22 · 2023: $613 · 2024: $962 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.30 | 2023-2025 | |
| Lilly USA, LLC | $325.93 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $257.16 | 2022-2024 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $162.96 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $160.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $103.48 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $46.80 | 2024-2025 | |
| Dexcom, INC. | $39.50 | 2023-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $37.31 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.86 | 2024 | Ofev, Jardiance |
| Janssen Pharmaceuticals, INC | $34.02 | 2025 | Spravato |
| Hologic Sales and Service, LLC | $22.33 | 2024 | Thinprep 2000 Processor, Third Wave, Aptima |
| Astellas Pharma US INC | $21.65 | 2023 | Myrbetriq |
| Novartis Pharmaceuticals Corporation | $19.69 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $17.57 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.18 | 2024 | Trintellix |
| Currax Pharmaceuticals LLC | $16.98 | 2025 | Contrave |
| Merck Sharp & Dohme LLC | $16.54 | 2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Almatica Pharma LLC | $13.73 | 2023 | Loreev Xr, Gralise |
| Astrazeneca Pharmaceuticals LP | $13.27 | 2023 | Farxiga |
| Eisai INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.